Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Embecta is a pure-play diabetes care company spun off from BD in April 2022, specializing in insulin delivery devices including pen needles, syringes, and safety products. The company generates ~$1.1B in revenue serving approximately 30 million people with diabetes globally, with significant exposure to US commercial and Medicare channels. The stock has been pressured by declining volumes in traditional insulin delivery as GLP-1 therapies reduce insulin dependency and biosimilar insulin adoption shifts delivery methods.
Embecta operates a razor-and-blade model selling consumable insulin delivery devices with high gross margins (63%) driven by manufacturing scale and established distribution relationships. Revenue is primarily volume-driven with limited pricing power due to GPO contracting and pharmacy benefit manager negotiations. The company benefits from sticky customer relationships as patients typically maintain consistent delivery device preferences, but faces structural headwinds from GLP-1 therapies reducing insulin usage intensity and biosimilar insulin adoption favoring different delivery formats. Geographic mix skews heavily toward US (~70% of revenue) with international presence in Europe and emerging markets.
US insulin delivery volumes - quarterly unit volume trends signal impact of GLP-1 therapy adoption on insulin usage
GLP-1 market penetration data - Ozempic, Mounjaro, and Wegovy adoption rates directly correlate with insulin demand destruction
Medicare Part D formulary decisions - coverage and reimbursement changes affect ~30-35% of revenue base
Biosimilar insulin launch dynamics - products like Semglee and Rezvoglar shift delivery method mix away from traditional syringes
Debt refinancing progress - company carries ~$1.3B debt from spin-off with elevated interest costs impacting cash flow
GLP-1 therapy adoption permanently reducing insulin-dependent diabetes population - Ozempic, Mounjaro, and Wegovy demonstrating 15-20% reductions in insulin requirements for Type 2 patients, with ~90% of diabetes market being Type 2
Biosimilar insulin proliferation shifting delivery methods - lower-cost biosimilars often packaged with prefilled pens rather than vials, reducing syringe demand and potentially disrupting pen needle market share
Continuous glucose monitoring and automated insulin delivery systems integration - closed-loop systems may favor proprietary delivery mechanisms over commodity pen needles
Medicare negotiation authority under Inflation Reduction Act - insulin price caps and potential device reimbursement changes could pressure pricing and utilization patterns
BD (former parent) retains significant diabetes care presence with integrated solutions and established relationships, creating competitive overlap
Novo Nordisk and Eli Lilly vertical integration - insulin manufacturers increasingly bundling delivery devices with pharmaceuticals, bypassing independent device suppliers
Private label and low-cost Asian manufacturers in pen needle market - commoditization pressure in undifferentiated product categories
Elevated leverage with negative equity position (-$2.32 D/E ratio) reflecting spin-off capital structure - limits financial flexibility and increases refinancing risk
Working capital intensity in inventory and receivables - medical device distribution requires significant working capital investment, pressuring cash conversion
Pension and post-retirement benefit obligations inherited from BD - potential unfunded liabilities not fully visible in summary metrics
low - Diabetes care products are non-discretionary medical consumables with utilization driven by disease prevalence rather than economic conditions. However, consumer out-of-pocket costs can affect compliance rates during economic stress, and healthcare utilization patterns (doctor visits, prescription fills) show modest correlation with employment and insurance coverage stability. The business is more sensitive to healthcare policy and pharmaceutical innovation cycles than GDP growth.
Rising interest rates increase debt service costs on the company's ~$1.3B term loan and revolving credit facilities, directly pressuring free cash flow available for debt reduction or potential shareholder returns. The spin-off capital structure was established in a low-rate environment, making the company vulnerable to refinancing risk. Higher rates also compress valuation multiples for low-growth healthcare businesses, as investors rotate toward higher-yielding alternatives. Limited impact on operational demand, as diabetes patients continue purchasing consumables regardless of rate environment.
Moderate exposure through hospital and distributor payment cycles, but the business primarily serves retail pharmacy channels with established payment terms. Credit conditions affect healthcare system capital spending and formulary decisions, though consumables are typically protected categories. The company's own credit profile matters significantly - elevated leverage (Debt/EBITDA ~3.5-4.0x estimated) constrains strategic flexibility and makes refinancing conditions critical to financial health.
value - The stock trades at distressed multiples (0.6x P/S, 5.2x EV/EBITDA) reflecting structural concerns about diabetes care market evolution. The 30% free cash flow yield attracts deep value investors betting on stabilization and debt paydown, while the negative equity and declining revenue deter growth-oriented funds. Special situations investors may view this as a potential restructuring or strategic alternative candidate given the challenged standalone profile. High short interest likely reflects skepticism about the company's ability to offset GLP-1 headwinds.
high - Small market cap ($600M) with limited float following spin-off creates liquidity-driven volatility. Stock is highly sensitive to diabetes care industry news, particularly GLP-1 clinical data and adoption trends. The -33% one-year return and -28% three-month decline demonstrate significant downside volatility, while lack of institutional sponsorship and negative sentiment create potential for sharp moves on any positive catalysts. Beta likely exceeds 1.5x relative to healthcare sector.
